Clinical trials: Peritoneal Malignancy, open to volunteers
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Surgery for Relapsed Ovarian Cancer in Precision
This multicenter, biomarker-driven, patient-centric study aimed to evaluate the efficacy of secondary cytoreduction followed by platinum-based chemotherapy in combination with anti-PD1/CTLA-4 bispecifics therapy in patients with…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT06602063
- Testing
- surgery/chemotherapy, Iparomlimab/Tuvonralimab
- Where
- 2 sites in China
- Volunteers
- 33 people
- Sponsor
- Shanghai Gynecologic Oncology Group
Gastric Cancer, Metastatic
A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer
This is a phase I, single arm, open-label clinical study of BioTTT001 in combination with SOX and Toraplizumab in patients with peritoneal metastases from gastric cancer.
- Trial name
- NCT06283121
- Testing
- BioTTT001 intraperitoneal infusion, SOX regimen, toripalimab
- Volunteers
- 30 people
- Sponsor
- China Medical University, China
Ovarian Cancer, Chemotherapeutic Toxicity
Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer
Rates of grade 3-4 toxicity with carboplatin and paclitaxel chemotherapy range 26-84%. Interventions to reduce toxicity are needed. Short term fasting protects against toxic effects of chemotherapy without decreasing efficacy.
- Trial name
- NCT05921149
- Testing
- Fasting Mimicking Diet (Xentigen by L'Nutra), Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- Endeavor Health
Cancer Harboring BRAF Alterations, HGG
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive…
- Conditions
- Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
- Trial name
- NCT05503797
- Testing
- Plixorafenib
- Where
- 70 sites in United States, Australia and 10 more
- Volunteers
- 254 people
- Sponsor
- Fore Biotherapeutics
Ovarian Cancer
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
The goal of this clinical trial is to learn about the side effects and effectiveness of this novel four-drug combination of chemotherapy (decitabine, selinexor, carboplatin and paclitaxel) on patients with relapsed ovarian…
- Trial name
- NCT05983276
- Testing
- Decitabine, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Loyola University
Ovarian Cancer, Fallopian Tube Cancer
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
This is an international, multicenter, randomized, open, Phase III trial to evaluate the efficacy and safety of carboplatin/paclitaxel/bevacizumab followed by bevacizumab and niraparib compared to carboplatin/paclitaxel followed…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT05009082
- Testing
- Carboplatin, Paclitaxel, Bevacizumab
- Where
- 65 sites in Germany
- Volunteers
- 970 people
- Sponsor
- AGO Study Group
Peritoneal (Metastatic) Cancer, Peritoneal Carcinomatosis
Heated Versus Aerosol-based Laparoscopic Chemotherapy for Cancer That Has Spread to the Peritoneum (Abdominal Lining)
This research study aims to improve the treatment of Peritoneal Carcinomatosis (PC), a condition where cancer spreads within the abdomen. Patients with PC often experience significant pain and nutritional problems.
- Conditions
- Peritoneal (Metastatic) Cancer, Peritoneal Carcinomatosis, Abdominal Cancer, Abdominal Cancer Patients
- Trial name
- Charlie-2 (NCT07282834)
- Testing
- Heated intra-peritoneal chemotherapy, Aerosolized intra-peritoneal chemotherapy
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Patrick Wagner, MD, FACS
Mesothelin Positive, Mesothelin-Expressing Tumors
A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer or Malignant Peritoneal Mesothelioma
Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory at Memorial Sloan Kettering to be changed (modified)…
- Conditions
- Mesothelin Positive, Mesothelin-Expressing Tumors, Esophageal Adenocarcinoma, Esophageal Adenocarcinomas
- Trial name
- NCT06623396
- Testing
- M28z1XXPD1DNR CAR
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Pleural Effusion, Malignant Ascites
Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer
The purpose of this study to find out if tocilizumab can be safely infused into chest or abdominal cavities of patients with malignancy ascites (MA) or malignant pleural effusions (MPE).
- Trial name
- RIOT2 (NCT06016179)
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Gastric Cancer (GC)
GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
This study is a single-arm, open-label clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of GK01 cell therapy in patients with gastric cancer and peritoneal metastasis.
- Trial name
- NCT07923396
- Testing
- GK01 combination with nab-paclitaxel and S-1
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Ruijin Hospital
Endometrioid Ovarian Cancer, Primary Peritoneal Cancer
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
The purpose of this study is to learn about the safety and tolerability of Cirtuvivint in combination with Olaparib in platinum resistant ovarian cancer.
- Conditions
- Endometrioid Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT06856499
- Testing
- Cirtuvivint, Olaparib
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Colorado, Denver
Ovarian Cancer
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
Ovarian cancer (OC) is a lethal disease. The purpose of this study is to assess the safety, pharmacokinetics and efficacy of ABBV901, alone or in combination with other anticancer drugs, in participants with ovarian cancer.
- Trial name
- NCT07278336
- Testing
- ABBV-901, Bevacizumab, Carboplatin
- Where
- 27 sites in United States, Australia and 6 more
- Volunteers
- 285 people
- Sponsor
- AbbVie
Ovarian Cancer, Fallopian Tube Carcinoma
SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer
This study is an open-label, dose-escalation, investigator-initiated phase I interventional clinical study. To evaluate the safety, tolerability and preliminary efficacy of SCT-001 CAR-T cell injection in subjects with relapsed…
- Conditions
- Ovarian Cancer, Fallopian Tube Carcinoma, Peritoneal Carcinoma
- Trial name
- NCT06846424
- Testing
- SCT-001 CAR-T cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai Gynecologic Oncology Group
Advanced Cancer, Metastatic Cancer
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: Find the recommended dose of ART0380 that can be given safely to participants…
- Conditions
- Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT04657068
- Testing
- ART0380, Gemcitabine, Irinotecan
- Where
- 88 sites in United States, France and 2 more
- Volunteers
- 542 people
- Sponsor
- Artios Pharma Ltd
Platinum Resistant Ovarian Cancer
Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer
The purpose of this Phase II study is to measure the effects of a combination of study drugs, losartan and paclitaxel, on platinum resistant ovarian cancer.
- Trial name
- NCT07265739
- Testing
- losartan, Paclitaxel
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Massachusetts General Hospital
Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)
This trial is a registered, phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with platinum-resistant recurrent epithelial ovarian cancer.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT06994195
- Testing
- BL-B01D1, Liposomal doxorubicin, Paclitaxel or Topotecan
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Gastric Cancer Peritoneal Metastases
A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10
This study aims to evaluate the efficacy and safety of HIPEC combined with NIPS and tislelizumab conversion therapy for gastric/gastroesophageal junction cancer with positive cytology alone (CY1P0) or a Peritoneal Carcinomatosis…
- Trial name
- NCT07304258
- Testing
- HIPEC, NIPS, Paclitaxel Injection, S-1, tislelizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hebei Medical University
Cancer, Breast Cancer
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic)
- Trial name
- SELECT-CAR-NK (NCT07410494)
- Testing
- EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
Fallopian Tube Cancer, Primary Peritoneal Cancer
A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)
The primary purpose of the study is to evaluate the efficacy of R-DXd with or without bevacizumab as maintenance therapy compared with standard of care (SOC) in participants with platinum-sensitive ovarian cancer (PSOC) as…
- Conditions
- Fallopian Tube Cancer, Primary Peritoneal Cancer, High-Grade Serous Ovarian Cancer, Endometrioid Epithelial Ovarian
- Trial name
- NCT07791732
- Testing
- R-DXd, Bevacizumab
- Volunteers
- 600 people
- Sponsor
- Daiichi Sankyo
Ovarian Cancer
A Study of SHR-A1811 in Subjects With Ovarian Cancer
This is an open-label study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with ovarian cancer.
- Trial name
- NCT06828354
- Testing
- SHR-A1811, Paclitaxel Injection, Doxorubicin Hydrochloride Liposome Injection
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.